Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Childhood brain tumors associated with rarely inherited BRCA2 gene mutations

15.10.2003


New research led by scientists at Memorial Sloan-Kettering Cancer Center and The Rockefeller University shows that pediatric brain tumors and Fanconi anemia can develop among children in the rare instance that both parents carry mutations of the BRCA2 gene. The work will be published in the October 15 issue of the Journal of the National Cancer Institute.



The report describes four families in which both parents carried BRCA2 mutations. The families were part of The International Fanconi Anemia Registry, a unique, prospectively collected database of approximately 1,000 patients with Fanconi anemia, a rare inherited disorder characterized by a severe deficiency of red blood cells, bone marrow failure, and a predisposition to cancer. The registry was established at The Rockefeller University in 1982 to address questions relating to diagnosis, prognosis, treatment, natural history of the disease, and cancer incidence in a large number of patients with this disorder.

According to the study, individual children from three of the families, and two distant cousins from the fourth family were born carrying two mutations of the BRCA2 gene, one inherited from each of their parents. In all four cases, the children were affected not only with Fanconi anemia, but also with brain tumors diagnosed at an average age of 3.5 years.


"These findings are the first to establish childhood brain cancers, predominantly medulloblastoma, as among the diseases that can occur if both parents carry BRCA2 mutations," said the study’s lead author Kenneth Offit, MD, Chief of the Clinical Genetics Service at Memorial Sloan-Kettering Cancer Center (MSKCC).

"It has been known that in rare cases, BRCA2 mutations can be inherited and cause Fanconi anemia," commented the study’s senior author Arleen Auerbach, PhD, Director of the International Fanconi Anemia Registry at The Rockefeller University.

"While brain tumors are extremely unusual in these patients, these results suggest that BRCA2 mutations may provide an important clue to the origin of these tumors," she said.

In the study, two of the four families with affected children carried a particular mutation of BRCA2 – the identical mutation in BRCA2 that is most frequency associated with an increased risk of breast and ovarian cancer in those of Ashkenazi Jewish ancestry. That mutation was first described by Dr. Offit’s group in 1996.

In the study, the authors recommend that individuals with BRCA2 mutations consider additional genetic counseling if their spouse is also at increased risk for having a BRCA2 mutation. In the rare circumstance that their partner also carries a BRCA2 mutation, there is the possibility that their offspring may be affected by Fanconi anemia and brain tumors.

However, according to the researchers, such cases are extremely rare. The chances of someone in the general population having a BRCA2 mutation are about 1 in 800; the risk is higher among individuals of Ashkenazi Jewish descent, approximately 1 in 100. In addition, while the total number of Fanconi anemia patients is not documented worldwide, scientists estimate that the likelihood of being a carrier for this disorder is somewhere between 1 in 300 and 1 in 100, the carrier frequency varying by ethnic group. If both parents carry a mutation in the same Fanconi anemia gene, each of their children has a 25 percent chance of inheriting the defective gene from both parents, which would cause the child to have the disorder.

"By studying the occurrence of very rare tumors in genetically defined populations, we have been able to learn much about the mechanisms of tumor development," said Dr. Auerbach.

Additional experiments are underway to analyze whether BRCA2 mutations are involved in other cases of childhood brain cancer among families in the registry.

"Our goal is to translate these findings regarding cancers of the brain and breast into better prevention and treatment strategies for these malignancies," said Dr. Offit.


The work was supported by the National Institutes of Health; the Lymphoma Foundation; the Danziger Foundation; the Koodish Fellowship; the Goldsmith Research Project; the Lomangino, Weissenbach, Southworth, and Niehaus Family Research Funds; the Elterninitiative Kinderkrebsklinik e. V.; and the Kinderstem e. V.

MSKCC is the world’s oldest and largest private institution devoted to prevention, patient care, research, and education in cancer. Our scientists and clinicians generate innovative approaches to better understand, diagnose and treat cancer. Our specialists are leaders in biomedical research and in translating the latest research to advance the standard of cancer care worldwide.

Esther Carver | EurekAlert!
Further information:
http://www.mskcc.org/

More articles from Health and Medicine:

nachricht Finding new clues to brain cancer treatment
21.02.2020 | Case Western Reserve University

nachricht UIC researchers find unique organ-specific signature profiles for blood vessel cells
18.02.2020 | University of Illinois at Chicago

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: A step towards controlling spin-dependent petahertz electronics by material defects

The operational speed of semiconductors in various electronic and optoelectronic devices is limited to several gigahertz (a billion oscillations per second). This constrains the upper limit of the operational speed of computing. Now researchers from the Max Planck Institute for the Structure and Dynamics of Matter in Hamburg, Germany, and the Indian Institute of Technology in Bombay have explained how these processes can be sped up through the use of light waves and defected solid materials.

Light waves perform several hundred trillion oscillations per second. Hence, it is natural to envision employing light oscillations to drive the electronic...

Im Focus: Freiburg researcher investigate the origins of surface texture

Most natural and artificial surfaces are rough: metals and even glasses that appear smooth to the naked eye can look like jagged mountain ranges under the microscope. There is currently no uniform theory about the origin of this roughness despite it being observed on all scales, from the atomic to the tectonic. Scientists suspect that the rough surface is formed by irreversible plastic deformation that occurs in many processes of mechanical machining of components such as milling.

Prof. Dr. Lars Pastewka from the Simulation group at the Department of Microsystems Engineering at the University of Freiburg and his team have simulated such...

Im Focus: Skyrmions like it hot: Spin structures are controllable even at high temperatures

Investigation of the temperature dependence of the skyrmion Hall effect reveals further insights into possible new data storage devices

The joint research project of Johannes Gutenberg University Mainz (JGU) and the Massachusetts Institute of Technology (MIT) that had previously demonstrated...

Im Focus: Making the internet more energy efficient through systemic optimization

Researchers at Chalmers University of Technology, Sweden, recently completed a 5-year research project looking at how to make fibre optic communications systems more energy efficient. Among their proposals are smart, error-correcting data chip circuits, which they refined to be 10 times less energy consumptive. The project has yielded several scientific articles, in publications including Nature Communications.

Streaming films and music, scrolling through social media, and using cloud-based storage services are everyday activities now.

Im Focus: New synthesis methods enhance 3D chemical space for drug discovery

After helping develop a new approach for organic synthesis -- carbon-hydrogen functionalization -- scientists at Emory University are now showing how this approach may apply to drug discovery. Nature Catalysis published their most recent work -- a streamlined process for making a three-dimensional scaffold of keen interest to the pharmaceutical industry.

"Our tools open up whole new chemical space for potential drug targets," says Huw Davies, Emory professor of organic chemistry and senior author of the paper.

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

70th Lindau Nobel Laureate Meeting: Around 70 Laureates set to meet with young scientists from approx. 100 countries

12.02.2020 | Event News

11th Advanced Battery Power Conference, March 24-25, 2020 in Münster/Germany

16.01.2020 | Event News

Laser Colloquium Hydrogen LKH2: fast and reliable fuel cell manufacturing

15.01.2020 | Event News

 
Latest News

Active droplets

21.02.2020 | Medical Engineering

Finding new clues to brain cancer treatment

21.02.2020 | Health and Medicine

Beyond the brim, Sombrero Galaxy's halo suggests turbulent past

21.02.2020 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>